Djibril Mbarushimana

Dr. Djibril Mbarushimana

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
MGMisbah Gashegu
Misbah Gashegu
VNVedaste Ndahindwa
Vedaste Ndahindwa
EREdson Rwagasore
Edson Rwagasore
ATAlbert Tuyishime
Albert Tuyishime
CMClarisse Musanabaganwa
Clarisse Musanabaganwa
Claude Mambo MuvunyiClaude Mambo Muvunyi
Claude Mambo Muvunyi
Background: The burden of bacterial bloodstream infections (BSIs) is rapidly increasing in Africa including Rwanda. Methods: This is a retrospective study that investigates the diversity, distribution, and antimicrobial susceptibility profiles of BSI bacteria in three tertiary referral hospitals in Rwanda between 2020 and 2022. Results: A total of 1532 blood culture tests were performed for visiting patients. Overall, the proportions of Gram-negative and Gram-positive bacteria were 48.2% and 51.8, respectively. Staphylococcus aureus was the predominant species accounting for 25% of all Gram-positive BSI species, and Klebsiella species represented 41% of all Gram-negative BSI species. Antimicrobial susceptibility testing revealed that Amikacin exhibited the highest activity against Enterobacter spp., Serratia spp., and Escherichia coli in >92% of cases and Klebsiella spp. in 75.7%. Meropenem and Imipenem were highly efficacious to Salmonella spp. (100% susceptibility), Enterobacter spp. (96.2% and 91.7%, respectively), and Escherichia coli (94.7% and 95.5%, respectively). The susceptibility of Enterococcus spp., S. aureus, and Streptococcus spp. to Vancomycin was 100%, 99.5%, and 97.1%, respectively. Klebsiella spp. was highly sensitive to Colistin (98.7%), Polymyxin B (85.6%), Imipenem (84.9%), and Meropenem (78.5%). Conclusions: We recommend strengthening the implementation of integrated transdisciplinary and multisectoral One Health including AMR stewardship for the surveillance, prevention, and control of AMR in Rwanda.

21 January 2026 in JMIR Formative Research
Verified
Journal Article
Open access
DMDjibril Mbarushimana
Djibril Mbarushimana
TATaofeek Adegboyega
Taofeek Adegboyega
GDGatera Jean Damascene
Gatera Jean Damascene
MBMuritala Issa Bale
Muritala Issa Bale
BDBuregeya Jean Damascene
Buregeya Jean Damascene
NCNgarambe Christian
Ngarambe Christian
Background: Antimicrobial resistance (AMR) poses a significant global health threat, requiring effective antimicrobial susceptibility testing (AST) and surveillance systems. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified critical gaps in the Laboratory Information System (LIS), including low capture rates for culture observation (60%) and AST data (25%), no standardization of AST panels (0%), and limited cumulative antibiogram generation (17%). Existing AMR surveillance platforms, such as the Information System for Monitoring Antimicrobial Resistance by the World Health Organization (WHO) Collaborating Center for Surveillance of Resistance to Antimicrobial Agents (WHONET), and the District Health Information System, operate as standalone systems separate from clinical workflows, which limits their real-time clinical utility. Objective: This study aimed to develop an enhanced, web-based LIS integrated within routine clinical care to improve AST reliability, enable real-time AMR surveillance at CHUB, and provide a scalable model for subnational and national surveillance networks in resource-limited settings, supporting antimicrobial stewardship. Methods: We developed an enhanced LIS using the OpenClinic GA, the current open-source hospital information system at CHUB, integrating Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and leveraging metadata from the AMR for R package, WHONET resources, and EUCAST Expert Rules. An agile development approach was used, incorporating a custom database schema, Java-based application programming interfaces (APIs), and web-based user interfaces. The system was designed to support minimum inhibitory concentration (MIC) and disk diffusion (DD) methods, automate result interpretation with color-coded outputs, WHO Access, Watch, Reserve (AWaRe)–based cascade reporting, and enable data export to WHONET for global surveillance. Results: The enhanced LIS improved AST data capture and standardization, providing reliable, automated result interpretation and real-time AMR surveillance capabilities. The system’s web-based architecture enables scalability through centralized deployment, allowing multiple facilities simultaneous access. Unlike standalone surveillance tools, the enhanced LIS integrates AST within electronic medical records, maintaining clinical information continuity from specimen registration through result reporting. The system supports immediate clinical decision through AWaRe–based cascade reporting, and automated resistance phenotype detection, followed by standardized WHONET-compatible exports for public health surveillance. Conclusions: This scalable, LIS model demonstrates the feasibility of implementing standards-based AMR informatics in resource-limited settings. By embedding surveillance within clinical workflows rather than treating it as a separate downstream activity, the system maximizes data quality and clinical relevance while minimizing staff burden. The centralized web-based architecture provides inherent scalability from facility to national levels, eliminating data fragmentation and ensuring metadata consistency across networks. Long-term sustainability requires continuous user training, designated personnel for metadata maintenance, local IT capacity building, and funding mechanisms beyond donor dependency. This model provides a practical roadmap for national digital stewardship programs, supporting both immediate patient care and long-term public health surveillance goals.

12 February 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
ESEmma Schallenberg
Emma Schallenberg
WLWelmoed van Loon
Welmoed van Loon
DMDjibril Mbarushimana
Djibril Mbarushimana
CIClement Igiraneza
Clement Igiraneza
KGKarolina Glanz
Karolina Glanz
FMFrank P Mockenhaupt
Frank P Mockenhaupt
Background: In many countries in Sub-Saharan Africa, the Plasmodium falciparum chloroquine resistance marker pfcrt K76T disappeared within a decade after use of chloroquine ceased. pfaat1 S258L has recently been implicated as another chloroquine resistance marker. Both genes may affect parasite susceptibility to partner drugs in artemisinin-based combination therapy. Rwanda abolished chloroquine use in 2001, and since 2006 the first-line antimalarial is artemether-lumefantrine. However, partial artemisinin resistance emerged in the region. We assessed the prevalence of pfcrt and pfaat1 markers in Huye district between 2010 and 2023, following trends and updating the status in southern Rwanda. Methods: P. falciparum-positive blood samples from community children and malaria patients collected in 2010, 2014, 2018, 2019, and 2023 were examined. pfcrt K76T was genotyped by restriction fragment length polymorphism, and pfaat1 S258L by high-resolution melting curve (2010–2019). Samples from 2023 were subjected to nanopore sequencing. Results: In 606 samples, pfcrt K76T prevalence declined from 76% (95% confidence interval [CI], 68%–83%) to 18% (95% CI, 11%–25%) between 2010 and 2018 but remained constant since at around 25% (P < .001). No other pfcrt markers were observed. pfaat1 S258L has remained at or near fixation. The artemisinin resistance marker pfk13 R561H was associated with pfcrt K76T (P = .02). Discussion: The persistence of pfcrt K76T 20 years after abolishing chloroquine use indicates ongoing drug selection or importation. The fixation of pfaat1 S258L argues against a major fitness cost of this variant in Huye. Increases in partial artemisinin resistance in Rwanda and molecular markers indicate compromised lumefantrine efficacy. The observed pfcrt and pfaat1 signatures in the study area might be of use in guiding artemisinin partner drug alternatives.

6 September 2023 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
WLWelmoed van Loon
Welmoed van Loon
RORafael Oliveira
Rafael Oliveira
CBClara Bergmann
Clara Bergmann
FHFelix HABARUGIRA
Felix HABARUGIRA
CTCostanza Tacoli
Costanza Tacoli
FMFrank P Mockenhaupt
Frank P Mockenhaupt
: Plasmodium vivax is the second-most common malaria pathogen globally, but is considered very rare in the predominantly Duffy-negative sub-Saharan African population. In 259 malaria patients from highland southern Rwanda, we assessed Plasmodium species and Duffy blood group status by polymerase chain reaction (PCR). Plasmodium falciparum, P. vivax, Plasmodium malariae, and Plasmodium ovale were seen in 90.7%, 8.1%, 11.6%, and 5.0%, respectively. Plasmodium vivax occurred more frequently as a monoinfection than in combination with P. falciparum. All P. vivax–infected individuals showed heterozygous Duffy positivity, whereas this was the case for only 3.1% of patients with P. falciparum monoinfection and malaria-negative control subjects (P < 0.01). Based on PCR diagnosis, P. vivax is not rare in southern Rwanda. All episodes of P. vivax were observed in heterozygous Duffy-positive patients, whereas elsewhere in Africa, P. vivax is also reported in Duffy-negative individuals. Refined mapping of Plasmodium species is required to establish control and elimination strategies including all malaria species.

22 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
GMGashegu Misbah
Gashegu Misbah
VNVedaste Ndahindwa
Vedaste Ndahindwa
EREdson Rwagasore
Edson Rwagasore
ATAlbert Tuyishime
Albert Tuyishime
CMClarisse Musanabaganwa
Clarisse Musanabaganwa
Claude Mambo MuvunyiClaude Mambo Muvunyi
Claude Mambo Muvunyi
The burden of bacterial bloodstream infections (BSIs) is rapidly increasing in Africa including Rwanda. This is a retrospective study investigates the diversity, distribution, and antimicrobial susceptibility profiles of BSIs bacteria in three tertiary referral hospitals in Rwanda between 2020 and 2022. A total of 1,532 blood culture tests were performed for visiting patients. Overall, the proportions of Gram-negative and Gram-positive bacteria were 48.2% and 51.8, respectively. Staphylococcus aureus was the predominant species accounting for 25% of all Gram-positive BSIs species and Klebsiella species representing 41% of all Gram-negative BSIs species. Antimicrobial susceptibility testing revealed that Amikacin exhibited the highest activity against Enterobacter spp., Serratia spp. and Escherichia coli in >92% of cases and Klebsiella spp. in 75.7%. Meropenem and Imipenem were highly efficacious to Salmonella spp. (100% susceptibility), Enterobacter spp. (96.2% and 91.7%, respectively), and Escherichia coli (94.7% and 95.5%, respectively). The susceptibility of Enterococcus spp., S. aureus, and Streptococcus spp. to Vancomycin was 100%, 99.5% and 97.1%, respectively. Klebsiella spp. was highly sensitive to Colistin (98.7%), Polymyxin B (85.6%), Imipenem (84.9%), and Meropenem (78.5%). We recommend strengthening the implementation of integrated transdisciplinary and multisectoral One Health including AMR-stewardship for the surveillance, prevention, and control of AMR in Rwanda.

24 May 2026 in JMIR Preprints
Verified
Preprint
Open access
DMDjibril Mbarushimana
Djibril Mbarushimana
TATaofeek Adegboyega
Taofeek Adegboyega
GDGatera Jean Damascene
Gatera Jean Damascene
MBMuritala Issa Bale
Muritala Issa Bale
BDBuregeya Jean Damascene
Buregeya Jean Damascene
CNChristian Ngarambe
Christian Ngarambe
BACKGROUND Antimicrobial resistance (AMR) is a global health emergency, disproportionately impacting sub-Saharan Africa where fragmented laboratory information systems (LIS) and inconsistent antimicrobial susceptibility testing (AST) practices limit both clinical decision-making and surveillance capacity. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified systemic gaps, including 0% AST panel standardization, 17% cumulative antibiogram generation capacity, and no enforcement of testing quality rules. A standards-based digital infrastructure integrating CLSI- and EUCAST-compliant AST panels into OpenClinic GA with bidirectional WHONet export was implemented in 2024. The implementing study expressly deferred quantitative key performance indicator (KPI) evaluation to allow sufficient post-implementation observation time. OBJECTIVE To quantify the impact of the implemented infrastructure on five KPI domains: (1) AST data capture volume and specimen throughput; (2) data standardization and ease of analysis; (3) laboratory turnaround time (TAT); (4) testing quality, including detection and resolution of specimen-antibiotic incompatibilities, method violations, and intrinsic resistance violations; and (5) antimicrobial resistance (AMR) profiles, including appropriate use of screener discs. METHODS A retrospective pre-post study compared Q1 2024 (pre-implementation; n=505 culture-positive specimens, legacy LIS export) with Q1 2026 (post-implementation; n=3,669 specimens, WHONet-format export) at CHUB. Outcomes included specimen throughput, nomenclature and data structure standardization, TAT (specimen receipt to results release, days), testing quality flags (Nitrofurantoin/Nalidixic acid on non-urine specimens; vancomycin by disc diffusion on staphylococci; ampicillin on intrinsically resistant Enterobacteriaceae), screener disc utilization (Pefloxacin, Cefoxitin), and resistance rates for key pathogens against CLSI 2024 breakpoints. RESULTS Specimen throughput increased 7.3-fold (+626%). Unique organism names decreased from 76 to 39 (-49%), with 11 non-standard spellings of Escherichia coli alone pre-implementation reduced to one WHO-standard entry. All 7,465 post-implementation records carried CLSI 2024 annotations versus 0% pre-implementation. Critical data-analysis fields, age categories, department, TAT timestamps, WHONET antibiotic codes, absent pre-implementation were fully present post-implementation. Pre-implementation errors included: 6 instances of Nitrofurantoin or Nalidixic acid on non-urine specimens, 4 instances of ampicillin on intrinsically resistant Enterobacteriaceae (including 1 spurious susceptible result), and 44 vancomycin results by disc diffusion on staphylococci and streptococci (16 on Staphylococcus aureus), an unreliable method per CLSI. All resolved to zero post-implementation. Screener disc use was transformed: Pefloxacin (fluoroquinolone surrogate for Enterobacteriaceae) was absent pre-implementation and introduced in 95 tests post-implementation; Cefoxitin (MRSA surrogate) was used without a systematic inferential framework pre-implementation (n=81, no inferential display) and formalised under the screener protocol post-implementation (n=33, MRSA rate 24.2%). Median TAT from specimen receipt to results release was 2.80 days (IQR 2.03-3.77). Among key pathogens, Escherichia coli ciprofloxacin resistance was 54.2% and ceftriaxone resistance 42.2%, while carbapenem susceptibility was preserved (imipenem resistance 1.5%). CONCLUSIONS Implementation of a CLSI/EUCAST-compliant digital AST and surveillance infrastructure at CHUB produced measurable, clinically meaningful improvements across all five KPI domains, yielding CHUB's first institution-wide cumulative antibiogram in GLASS-compatible WHONet format. These results fulfill the deferred quantitative evaluation and provide a replicable evidence base for tertiary institutions across sub-Saharan Africa. INTERNATIONAL REGISTERED REPORT RR2-10.2196/82727